Dutch-Russian polio vaccine
Russian biotechnological company "Nanolek"
will begin production of inactivated polio vaccine
On November 14, 2012, Nanolek announced the conclusion of a number of agreements with the Dutch vaccine manufacturer Bilthoven Biologicals.
The main subject of the agreements is the creation of a ready-made form of inactivated polio vaccine (IPV) on the territory of the Russian Federation.
According to the WHO program to stop the use of oral (live) polio vaccine (OPV), within the framework of the Global Polio Eradication Initiative program, it is planned to stop the use of OPV in the world in the coming years. Currently, inactivated polio vaccine is not produced on the territory of the Russian Federation and CIS countries. As part of the implementation of the state policy "Pharma 2020", by order of the Government of the Russian Federation No. 1141-r965 dated 0623.070.20102009, IPV is included in the list of strategically important medicines, the production of which should be provided on the territory of the Russian Federation.
In accordance with the signed agreements, Bilthoven Biologicals grants Nanolek an exclusive license for the production, marketing and distribution of the finished form of the IPV vaccine on the territory of the Customs Union (Russia, Belarus, Kazakhstan), and also undertakes obligations to train employees in raw material processing technology and product quality control. The production of the finished form of IPV will be organized on the territory of the Nanolek biotechnological complex under construction in the Kirov region.
This agreement will fully meet the needs of the population of the Russian Federation and CIS countries in inactivated polio vaccine, as well as develop their own combined vaccines with a full set of antigens recommended by the National Calendar of Preventive Vaccinations of the Russian Federation.
The agreements were concluded through the mediation of the consulting company Sarvac Ltd.
The financial terms of the transaction were not disclosed.
The Nanolek company is a dynamically developing innovative biotechnological company.
Nanolek together with Rusnano are implementing a project for the construction of a modern biotechnological complex in the Kirov region.
The priority activity of the company is the development and production of pharmaceutical and biotechnological preparations, including those based on nanotechnology and nanomaterials.
Project products:
- vaccines
- ointments and gels based on organogel
- advanced drugs with the addition of silicon nanocarriers
The company "Bilthoven Biologicals", formerly known as the Netherlands Vaccine Institute (NVI), has been specializing in the production of a full cycle of vaccines since 1909. Today it is believed that 33% of all the world's pediatric vaccines are produced based on the technologies of the company "Bilthoven Biologicals".
Together with the new owner of the company, the Indian Institute of Serums (Serum Institute of India) – the largest manufacturer of vaccines in the world, Bilthoven Biologicals directs its efforts to save people's lives, produce enough vaccines at affordable prices for the prevention of infectious diseases.
Portal "Eternal youth" http://vechnayamolodost.ru15.11.2012